OKYO Pharma Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OKYO research report →
Companywww.okyopharma.com
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
- CEO
- Robert J. Dempsey
- IPO
- 2022
- Employees
- 3
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $61.39M
- P/E
- -12.98
- P/S
- 0.00
- P/B
- -17.53
- EV/EBITDA
- -5.98
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 102.92%
- ROIC
- 154.22%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,706,292 · 72.03%
- EPS
- $-0.12 · -19900.00%
- Op Income
- $-7,188,875
- FCF YoY
- 80.91%
Performance & Tape
- 52W High
- $3.35
- 52W Low
- $1.44
- 50D MA
- $1.61
- 200D MA
- $2.05
- Beta
- -0.05
- Avg Volume
- 115.10K
Get TickerSpark's AI analysis on OKYO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | JACOB GARY S | other | 0 |
| Mar 14, 27 | JACOB GARY S | other | 21,154 |
| Mar 13, 25 | JACOB GARY S | other | 16,667 |
| Jan 29, 28 | JACOB GARY S | other | 102,564 |
| Mar 25, 29 | JACOB GARY S | other | 50,000 |
| Jul 16, 29 | JACOB GARY S | other | 89,356 |
| Mar 18, 26 | CERRONE GABRIELE M | other | 0 |
| Oct 27, 23 | CERRONE GABRIELE M | other | 70,071 |
| Oct 23, 23 | CERRONE GABRIELE M | other | 499,468 |
| Sep 15, 23 | BRANCACCIO JOHN P | buy | 16,670 |
Our OKYO Coverage
We haven't published any research on OKYO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OKYO Report →